Stereotaxis Announces Publication of Clinical Research Supplement Highlighting Robotic Navigation for Cardiac Arrhythmias

May 1, 2018

ST. LOUIS, May 01, 2018 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (OTCQX:STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced that the Society for Cardiac Robotiic Navigation (SCRN) has published a supplement in the European Journal of Pacing, Arrhythmias and Cardiac Electrophysiology of the European Heart Rhythm Association and the European Society of Cardiology (EP Europace). The title of the supplement is “Update on Clinical Applications for Robotic Magnetic Navigation for Cardiac Arrhythmia” and can be accessed at https://academic.oup.com/europace/issue/20/suppl_2. The journal aims to provide an avenue of communication of top quality global original scientific work and reviews in the fields of arrhythmias, pacing and cellular electrophysiology.

“The SCRN was established with the intention of providing a platform for users of cardiac robotic technologies,” said Dr. Tamas Szili-Torok, current president of the SCRN and co-guest editor of the supplement. “The papers included in this supplement were obtained through a competitive application process and were subject to peer review, providing the latest data available on robotic applications in electrophysiology.”

The supplement includes 8 publications on data collected and analyzed by physicians at 15 hospitals and universities throughout North America, Europe, Australia, and China.

Dr. Eugene Crystal, incoming president of the SCRN and co-guest editor, added, “Publishing the latest clinical evidence in a well-respected journal in the focused issue is extraordinarily important for the SCRN mission of educating current and future operators worldwide. This supplement will provide some experimental and key clinical data on a broad range of arrhythmias including those that are difficult or impossible to treat with conventional approaches. In addition to the latest safety and efficacy data on robotic EP procedures, new data is available supporting catheter stability and the contact force exhibited from the magnetic catheter. The editorial board made specific focused efforts to help the authors shape this manuscript to the best technical details of clinical application for remote magnetic navigation.”

The EP Europace supplement will be highlighted at the upcoming Heart Rhythm Society annual meeting in Boston. Key contributors of the supplement will be available at 4:30 PM Wednesday, May 9, 2018 at booth #537, to discuss the data published in the supplement and printed copies will be available.

This supplement was supported by an educational grant from the SCRN and an unrestricted educational grant from Stereotaxis, Inc.

About Stereotaxis
Stereotaxis is the global leader in innovative robotic technologies designed to enhance the treatment of arrhythmias and perform endovascular procedures. Its mission is the discovery, development and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide unsurpassed patient care with robotic precision and safety, improved lab efficiency and productivity, and enhanced integration of procedural information. Over 100 issued patents support the Stereotaxis platform. The core components of Stereotaxis' systems have received regulatory clearance in the United States, European Union, Japan, Canada, China, and elsewhere. For more information, please visit www.stereotaxis.com.

This press release includes statements that may constitute “forward-looking” statements, usually containing the words “believe”, “estimate”, “project”, “expect” or similar expressions. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, the Company’s ability to raise additional capital on a timely basis and on terms that are acceptable, its ability to continue to manage expenses and cash burn rate at sustainable levels, its ability to continue to work with lenders to extend, repay or refinance indebtedness, or to obtain additional financing, in either case on acceptable terms, continued acceptance of the Company's products in the marketplace, the effect of global economic conditions on the ability and willingness of customers to purchase its systems and the timing of such purchases, competitive factors, changes resulting from healthcare reform in the United States, including changes in government reimbursement procedures, dependence upon third-party vendors, timing of regulatory approvals, and other risks discussed in the Company's periodic and other filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release. There can be no assurance that the Company will recognize revenue related to its purchase orders and other commitments in any particular period or at all because some of these purchase orders and other commitments are subject to contingencies that are outside of the Company’s control. In addition, these orders and commitments may be revised, modified, delayed or canceled, either by their express terms, as a result of negotiations, or by overall project changes or delays.

Stereotaxis Contacts:  
David Fischel  
Chairman and Chief Executive Officer  
Martin C. Stammer  
Chief Financial Officer

314-678-6100  
investors@stereotaxis.com